Scanning Electron Microscopy of Conjunctival Scraping: Our Experience in the Diagnosis of Infectious Keratitis with Negative Culture Tests
Abstract
:1. Introduction
2. Materials and Methods
2.1. Samples Collection
2.2. Scanning Electron Microscopy Examination
3. Results
Patients Clinical Data
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Dahlgren, M.A.; Lingappan, A.; Wilhelmus, K.R. The Clinical Diagnosis of Microbial Keratiti. AJO 2007, 143, 940–944. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rietveld, R.P.; Riet, G.T.; Bindels, P.J.E.; Sloos, J.H.; Van Weert, H.C.P.M. Predicting bacterial cause in infectious conjunctivitis: Cohort study on informativeness of combinations of signs and symptoms. BMJ 2004, 329, 206–210. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Thanathanee, O.; O’Brien, T.P. Conjunctivitis: Systematic Approach to Diagnosis and Therapy. Curr. Infect. Dis. Rep. 2011, 13, 141–148. [Google Scholar] [CrossRef] [PubMed]
- O’Brien, T.P.; Jeng, B.H.; McDonald, M.; Raizman, M.B. Acute conjunctivitis: Truth and misconceptions. Curr. Med. Res. Opin. 2009, 25, 1953–1961. [Google Scholar] [CrossRef] [PubMed]
- Dart, J.K.G.; Saw, V.P.J.; Kilvington, S. Acanthamoeba Keratitis: Diagnosis and Treatment Update. AJO 2009, 148, 487–499. [Google Scholar] [CrossRef]
- Kaminskyj, S.G.W.; Dahms, T.E.S. High spatial resolution surface imaging and analysis of fungal cells using SEM and AFM. Micron 2008, 39, 49–61. [Google Scholar] [CrossRef] [PubMed]
- Carter, H.W. Clinical applications of scanning electron microscopy (SEM) in North America with emphasis on SEM’s role in comparative microscopy. Scan. Electron Microsc. 1980, 154, 115–120. [Google Scholar] [PubMed]
- Kenemans, P.; HafezClinical, E.S. Clinical application of scanning electron microscopy in human reproduction. Scan. Electron Microsc. 1984, Pt 1, 215–242. [Google Scholar] [PubMed]
- Bergmans, L.; Moisiadis, P.; Van Meerbeek, B.; Quirynen, M.; Lambrechts, P. Microscopic observation of bacteria: Review highlighting the use of environmental SEM. Int. Endod. J. 2005, 38, 775–788. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- De Souza, W.; Campanati, L.; Attias, M. Strategies and results of field emission scanning electron microscopy (FE-SEM) in the study of parasitic protozoa. Micron 2008, 39, 77–87. [Google Scholar] [CrossRef] [PubMed]
- Cennamo, G.; Del Prete, A.; Forte, R.; Del Prete, S.; Marasco, D. Impression cytology with scanning electron microscopy: A new method in the study of conjunctival microvilli. EYE 2008, 22, 138–143. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Forte, R.; Cennamo, G.; Del Prete, S.; Napolitano, N.; Del Prete, A. Allergic Conjunctivitis and Latent Infections. Cornea 2009, 28, 839–842. [Google Scholar] [CrossRef] [PubMed]
- Forte, R.; Cennamo, G.; Del Prete, S.; Cesarano, I.; Del Prete, A. Scanning Electron Microscopy of Corneal Epithelium in Soft Contact Lens Wearers. Cornea 2010, 29, 732–736. [Google Scholar] [CrossRef]
- Meloni, M.; De Servi, B.; Marasco, D.; Del Prete, S. Molecular mechanism of ocular surface damage: Application to an in vitro dry eye model on human corneal epithelium. Mol. Vis. 2011, 17, 113–126. [Google Scholar] [PubMed]
- Cennamo, G.; Forte, R.; Del Prete, S.; Cardone, D. Scanning Electron Microscopy Applied to Impression Cytology for Conjunctival Damage From Glaucoma Therapy Published. Cornea 2013, 32, 1227–1231. [Google Scholar] [CrossRef] [PubMed]
- Del Prete, S.; Marasco, D.; Del Prete, A.; Meloni, M.; Grumetto, L.; Russo, G. Scraping cytology and scanning electron microscopy in diagnosis and therapy of corneal ulcer by mycobacterium infection. Arch. Case Rep. 2019, 3, 50–53. [Google Scholar] [CrossRef] [Green Version]
- Gopinathan, U.; Sharma, S.; Garg, P.; Rao, G.N. Review of epidemiological features, microbiological diagnosis and treatment outcome of microbial keratitis: Experience of over a decade. Indian J. Ophthalmol. 2009, 57, 273–279. [Google Scholar] [CrossRef]
- Boralkar, A.N.; Dindore, P.R.; Fule, R.P.; Bangde, B.N.; Albel, M.V.; Saoji, A.M. Microbiological studies in conjunctivitis. Indian J. Ophthalmol. 1989, 37, 94–95. [Google Scholar]
ID Patient | Age/ Sex | Systemic Pathologies | Ocular Pathology | Microorganisms | Therapy | Resolution Time |
---|---|---|---|---|---|---|
1 | 42/m | Hypertension | Keratoconjunctivitis | Candida Mycobacterium | Fluconazole 0.2% Chlortetracycline 1% | 21 days |
2 | 37/f | -- | Keratitis | Mycoplasma Aspergillus | Chlortetracycline Fluconazole Povidone-iodine | 21 days |
3 | 47/m | -- | Keratoconjunctivitis | Candida Acanthamoeba | Chlorhexidine 0.2% Fluconazole 0.2% PHMB 0.2% | 35 days |
4 | 59/m | Hypertension | Keratoconjunctivitis | None (Epith.metaplasia) | Hydrocortisone Ialuronic Acid | 28 days |
5 | 48/f | -- | Keratoconjunctivitis | Micrococci | Chlortetracycline | 21 days |
6 | 64/f | Hypertension Dyslipidemia | Keratoconjunctivitis | Mycoplasma Pseudomonas | Chlortetracycline Levofloxacin | 21 days |
7 | 61/f | Dysthyroidism | Keratoconjunctivitis | Candida | Fluconazole | 21 days |
8 | 18/m | Hypertension Dyslipidemia Cardiopathy | Keratoconjunctivitis | Mycoplasma Chlamydia Criptococcus | Chlortetracycline Fluconazole Chlorhexidine 0.2% | 35 days |
9 | 55/f | Cancer | Keratoconjunctivitis | Cocci | Gentamicin Ciprofloxacin | 14 days |
10 | 56/m | Psychosis Dyslipidemia | Keratoconjunctivitis | Mycoplasma Acanthamoeba | Chlortetracycline PHMB 0.2% Chlorhexidine 0.2% | 35 days |
11 | 48/m | Keratoconjunctivitis | Mycobacterium | Chlortetracycline Azithromycin | 21 days | |
12 | 63/m | Diabetes Hypertension | Corneal Ulcer | Acanthamoeba Candida Cocci | PHMB 0.2% Chlorhexidine 0.2% Ciprofloxacin | 28 days |
13 | 67/f | Hypertension Dyslipidemia | Keratoconjunctivitis | Mycoplasma | Chlortetracycline Lomefloxacin | 21 days |
14 | 60/m | Hypertension | Corneal infiltrates | Mycobacterium Cladosporium | Chlortetracycline Fluconazole | 21 days |
15 | 40/m | --- | Corneal Ulcer | Acanthamoeba Candida Micrococci | PHMB 0.2% Fluconazole Chlorhexidine 0.2% Levofloxacin | 35 days |
16 | 53/f | --- | Corneal abscess | Candida | Voriconazole 0.2% | 21 days |
17 | 15/f | --- | Keratoconjunctivitis | Mycoplasma | Chlortetracycline Levofloxacin | 28 days |
18 | 51/m | --- | Keratoconjunctivitis | Acanthamoeba HSV I | PHMB 0.2% Chlorhexidine 0.2% Acyclovir | 42 days |
19 | 71/f | Diabetes | Keratoconjunctivitis | Micrococci | Tetracycline | 21 days |
20 | 29/m | Prostatitis | Keratitis | Candida Acanthamoeba | Fluconazole PHMB 0.2% Chlorhexidine 0.2% | 28 days |
21 | 75/f | Hypertension Cardiopathy Dyslipidemia Diabetes | Keratitis | Acanthamoeba | PHMB 0.2% Chlorhexidine 0.2% Chloramphenicol | 42 days |
22 | 69/f | Hypertension Cardiopathy Diabetes | Keratitis | Mycoplasma | Chlortetracycline | 35 days |
23 | 40/f | --- | Keratoconjunctivitis | HSVI | Acyclovir Chlorhexidine 0.2% | 14 days |
24 | 30/f | --- | Keratoconjunctivitis | Mycoplasma Acanthamoeba | Chlortetracycline PHMB 0.2% Chlorhexidine 0.2% | 35 days |
25 | 41/f | --- | Keratitis | Cocci | Chloramphenicol Chlortetracycline | 10 days |
26 | 25/m | Hypertension Cardiopathy | Keratoconjunctivitis | Mycobacterium | Chlortetracycline Chlorhexidine 0.2% | 28 dys |
27 | 60/m | Hypertension Diabetes | Keratoconjunctivitis | Candida Acanthamoeba | Fluconazole PHMB 0.2% Chlorhexidine 0.2% | 35 days |
28 | 66/f | Hypertension Diabetes | Keratoconjunctivitis | Acanthamoeba Chlamydia | PHMB 0.2% Chlorhexidine 0.2% Chlortetracycline | 35 days |
29 | 60/m | Hypertension Diabetes | Keratoconjunctivitis | Candida | Fluconazole | 28 days |
30 | 44/m | -- | Keratoconjunctivitis | Chlamydia Mycoplasma | Chlortetracycline Chloramphenicol | 21 days |
31 | 58/m | Hypertension Dyslipidemia | Keratoconjunctivitis | Candida Micobacterium | Fluconazole Chlortetracycline Ofloxacin | 28 days |
32 | 39/m | --- | Keratoconjunctivitis | None (Eosinofils) | Ketotifen Hydrocortisone Ialuronic Acid | 14 days |
33 | 60/m | Hypertension | Keratoconjunctivitis | Candida Acanthamoeba | Fluconazole PHMB 0.2% Chlorhexidine 0.2% | 28 days |
34 | 57/m | --- | Keratoconjunctivitis | Acanthamoeba Micobacterium | PHMB 0.2% Chlorhexidine 0.2% Chlortetracycline | 35 days |
35 | 62/m | --- | Keratoconjunctivitis | Mycoplasma Pseudomonas | Levofloxacin Chlorhexidine 0.2% Chlortetracycline | 21 days |
36 | 73/f | Hypertension Diabetes | Keratitis | Candida | Fluconazole Chlorhexidine | 32 days |
37 | 52/f | Hypothyroidism | Keratoconjunctivitis | Chlamydia HSV II | Chlortetracycline Acyclovir, Ofloxacin | 28 days |
38 | 43/f | Polycystic ovary | Keratoconjunctivitis | Candida | Fluconazole Chlortetracycline | 21 days |
39 | 66/m | Hypertension | Keratoconjunctivitis | Candida Acanthamoeba | FluconazolePHMB 0.2% Chlorhexidine 0.2% | 42 days |
40 | 35/m | --- | Keratoconjunctivitis | Mycobacterium | Chlortetracycline Sulfamethoxazole | 21 days |
41 | 60/f | --- | Keratoconjunctivitis | Aspergillus fumigatus | Fluconazole Povidone-iodine (PVP-I) | 28 days |
42 | 56/f | Dysthyroidism | Keratoconjunctivitis | Mycobacterium NTN | Chlortetracycline Povidone-iodine (PVP-I) | 21 days |
43 | 55/f | --- | Keratitis | Acanthamoeba | PHMB 0.2% Chlorhexidine 0.2% | 35 days |
44 | 52/m | --- | Keratoconjunctivitis | Mycoplasma Acanthamoeba | Chlortetracycline PHMB 0.2% Chlorhexidine 0.2% | 28 days |
45 | 70/f | Hypertension Dyslipidemia Cardiopathy | Corneal Infiltrates | Candida Acanthamoeba Micrococci | Fluconazole PHMB 0.2% Chlorhexidine 0.2% Ciprofloxacin | 49 days |
46 | 67/f | Hypertension | Keratitis punctata | None (Globet cells deficit) | Ialuronic Acid Hydrocortisone Carbopol gel | 14 days |
47 | 2/f | Hypertension | Keratoconjunctivitis | Candida | Fluconazole Chlorhexidine 0.2% | 28 days |
48 | 61/f | Keratoconjunctivitis | Acanthamoeba Mycoplasma | PHMB 0.2% Chlorhexidine 0.2% Chlortetracycline Chloramphenicol | 35 days | |
49 | 42/m | --- | Keratoconjunctivitis | Mycoplasma Cocci | Chlortetracycline Levofloxacin | 21 days |
50 | 34/f | --- | Keratoconjunctivitis | Acanthamoeba Candida | PHMB 0.2% Chlorhexidine 0.2% Fluconazole | 35 days |
51 | 69/f | Psoriasis | Keratoconjunctivitis | Acanthamoeba Candida | PHMB 0.2% Chlorhexidine 0.2% Fluconazole | 35 days |
52 | 53/f | --- | Keratoconjunctivitis | Mycoplasma Candida Chlamydia | Chlortetracycline Fluconazole Azithromycin | 21 days |
53 | 64/f | Hypertension Cardiopathy | Keratoconjunctivitis | Mycobacterium | Chlortetracycline Cloramphenicol | 21 days |
54 | 66/m | Hypertension | Keratoconjunctivitis | Pseudomonas | Gentamicin Lomefloxacin | 14 days |
55 | 63/f | Hypertension Dyslipidemia | Keratoconjunctivitis | Mycoplasma Aspergillus | Chlortetracycline Fluconazole Chlorhexidine 0.2% | 28 days |
56 | 56/f | Hypertension Diabetes Dyslipidemia | Keractoconjunctivitis | Acanthamoeba | PHMB 0.2% Chlorhexidine 0.2% | 35 days |
57 | 75/f | Hypertension | Keratitis | Candida | Fluconazole Povidone-iodine (PVP-I) | 28 days |
58 | 66/f | Hypertension | Keratoconjunctivitis | Chlamydia | Chlortetracycline Azithromycin | 21 days |
59 | 62/m | Cancer | Keratoconjunctivitis | Acanthamoeba | PHMB 0.2% Chlorhexidine 0.2% Chlortetracycline | 28 days |
60 | 86/f | Dysthyroidism Parkinson disease | Keratoconjunctivitis | Mycoplasma Chlamydia | Chlortetracycline Lomefloxacin | 28 days |
61 | 54/m | Hypertension | Keratoconjunctivitis | Candida Mycoplasma | Fluconazole Chlortetracycline Chlorhexidine 0.2% | 21 days |
62 | 33/m | --- | Keratitis punctata | None (Eosinophils) | Olopatadine Hyaluronic acid Spaglumic Acid | 18 days |
63 | 43/m | Hypertension | Keratoconjunctivitis | Chlamydia | Chlortetracycline Azytromicin | 28 days |
64 | 35/f | --- | Keratoconjunctivitis | Mycoplasma | Chlortetracycline Spaglumic Acid | 21 days |
65 | 38/m | Polycystic ovary | Keratoconjunctivitis | Candida Acanthamoeba | Fluconazole PHMB 0.2% Chlorhexidine 0.2% | 35 days |
Sem Examination | Microbiologic Cultures | ||
---|---|---|---|
Advantages | Disadvantages | Advantages | Disadvantages |
|
|
|
|
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Troisi, M.; Del Prete, S.; Troisi, S.; Marasco, D.; Costagliola, C. Scanning Electron Microscopy of Conjunctival Scraping: Our Experience in the Diagnosis of Infectious Keratitis with Negative Culture Tests. Reports 2023, 6, 10. https://doi.org/10.3390/reports6010010
Troisi M, Del Prete S, Troisi S, Marasco D, Costagliola C. Scanning Electron Microscopy of Conjunctival Scraping: Our Experience in the Diagnosis of Infectious Keratitis with Negative Culture Tests. Reports. 2023; 6(1):10. https://doi.org/10.3390/reports6010010
Chicago/Turabian StyleTroisi, Mario, Salvatore Del Prete, Salvatore Troisi, Daniela Marasco, and Ciro Costagliola. 2023. "Scanning Electron Microscopy of Conjunctival Scraping: Our Experience in the Diagnosis of Infectious Keratitis with Negative Culture Tests" Reports 6, no. 1: 10. https://doi.org/10.3390/reports6010010
APA StyleTroisi, M., Del Prete, S., Troisi, S., Marasco, D., & Costagliola, C. (2023). Scanning Electron Microscopy of Conjunctival Scraping: Our Experience in the Diagnosis of Infectious Keratitis with Negative Culture Tests. Reports, 6(1), 10. https://doi.org/10.3390/reports6010010